Victory Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,066,208 shares of the company’s stock after acquiring an additional 1,799 shares during the period. Victory Capital Management Inc.’s holdings in Eli Lilly and were worth $157,820,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of LLY. Coastal Capital Group Inc. boosted its holdings in shares of Eli Lilly and by 153.8% during the second quarter. Coastal Capital Group Inc. now owns 165 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the last quarter. Price Wealth LLC boosted its holdings in shares of Eli Lilly and by 75.0% during the third quarter. Price Wealth LLC now owns 182 shares of the company’s stock worth $27,000 after purchasing an additional 78 shares during the last quarter. Hoover Financial Advisors Inc. acquired a new stake in shares of Eli Lilly and during the second quarter worth $33,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and during the third quarter worth $55,000. Finally, Truvestments Capital LLC boosted its holdings in shares of Eli Lilly and by 79.9% during the second quarter. Truvestments Capital LLC now owns 358 shares of the company’s stock worth $58,000 after purchasing an additional 159 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
In other Eli Lilly and news, SVP Melissa S. Barnes sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $151.01, for a total transaction of $755,050.00. Following the transaction, the senior vice president now owns 23,580 shares in the company, valued at $3,560,815.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.09% of the company’s stock.
Several equities research analysts have recently issued reports on the company. ValuEngine cut Eli Lilly and from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Sanford C. Bernstein initiated coverage on Eli Lilly and in a report on Tuesday, November 10th. They issued a “market perform” rating and a $150.00 target price on the stock. Truist initiated coverage on Eli Lilly and in a report on Friday, October 23rd. They issued a “buy” rating and a $180.00 target price on the stock. Finally, Berenberg Bank initiated coverage on Eli Lilly and in a report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 target price on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $168.07.
Shares of LLY traded up $0.57 during midday trading on Tuesday, reaching $141.16. 21,028 shares of the company were exchanged, compared to its average volume of 3,963,427. The stock has a 50-day moving average price of $143.73 and a 200-day moving average price of $152.01. The company has a market cap of $134.49 billion, a price-to-earnings ratio of 23.13, a P/E/G ratio of 1.35 and a beta of 0.27. Eli Lilly and Company has a 1-year low of $112.86 and a 1-year high of $170.75. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Sunday, November 1st. The company reported $1.54 EPS for the quarter, missing the Zacks’ consensus estimate of $1.71 by ($0.17). The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.87 billion. Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.48 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 7.26 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.10%. The ex-dividend date is Thursday, November 12th. Eli Lilly and’s dividend payout ratio is presently 49.01%.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Further Reading: What Are Treasury Bonds?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.